ClinicalTrials.gg

Program

VH4367310

A development code.

In GlaxoSmithKline's pipeline, HIV integrase inhibitor. Its studies are mostly in HIV Infections, led by GlaxoSmithKline.

Furthest: phase 1, since Sep 8, 20261 company-led study, 1 open or runningNext primary completion: Dec 26, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline11 open or runningphase 1since Sep 8, 2026Sep 8, 2026Dec 26, 2028phase 1 · NCT07818915
  • Named in GlaxoSmithKline’s own pipeline as VH4367310, phase 1, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 8, 2026First study: phase 1 study in HIV InfectionsFirst studyNCT07818915 · 112 planned · United States

Ahead

  1. Dec 26, 2028Primary completion: phase 1 study in HIV InfectionsNCT07818915

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“HIV integrase inhibitor”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07818915HIV Infections · United States1RecruitingDec 26, 2028112

How it is read

Names in the registry

  • “VH4367310”, 1 entry

Codes read as this program: VH4367310.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.